Equillium, Inc. (EQ) NASDAQ
2.47
+0.4(+19.32%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.47
+0.4(+19.32%)
Currency In USD
| Previous Close | 2.07 |
| Open | 2.41 |
| Day High | 2.63 |
| Day Low | 2.27 |
| 52-Week High | 2.63 |
| 52-Week Low | 0.27 |
| Volume | 4.68M |
| Average Volume | 627,171 |
| Market Cap | 87.74M |
| PE | -4.26 |
| EPS | -0.58 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 1.14 |
| Change | 0.4 |
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
GlobeNewswire Inc.
Feb 25, 2026 1:30 PM GMT
LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fire
Equillium to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory diso
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 03, 2025 9:05 PM GMT
LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on October 31, 2025, the Compensation